Literature DB >> 10896252

Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro.

J B Hansen1, B Svensson, R Olsen, M Ezban, B Osterud, R H Paulssen.   

Abstract

TFPI is a potent inhibitor of the extrinsic coagulation system constitutively synthesized by endothelial cells. A major portion of intravascular TFPI is stored associated with endothelial cells. and administration of unfractionated heparin (UFH) in vivo causes a prompt mobilization of TFPI into the circulation. The present study was conducted to investigate how UFH affected the synthesis, secretion and anticoagulant potency of TFPI in endothelial cells in vitro. A spontaneously transformed immortal endothelial cell line was used (ECV304). Stimulation of ECV304 cells with UFH caused a prompt dose-dependent (0-5 IU UFH/ml) release of TFPI to the medium accompanied by no change of TFPI at the surface membrane assessed by immunocytochemical methods. Northern blot analysis revealed two mRNA transcripts for TFPI with a molecular size of 1.4 kb and 4.4 kb, respectively. Stimulation of ECV304 cells for 24 hrs with various concentrations of UFH caused a dose-dependent increase of TFPI in the medium (6.2-29.6 ng/10(6) cells within the concentration range 0-10 IU/ml). A similar dose-dependent increase in the expression of both TFPI mRNA species was observed. Long-term incubation of ECV304 cells with 5.0 IU/ml UFH caused a 5-10 fold increase in the TFPI concentration accumulated in the medium over 48 hrs. The increased TFPI mRNA expression induced by UFH appeared already after 10 min, peaked after 2-4 hrs, remained augmented throughout the entire period of UFH exposure, and preceded the synthesis-dependent increase in TFPI release by 2-4 hrs. The procoagulant activity of the cells was downregulated by 36% and the contribution of TFPI to the anticoagulant potency of ECV304 cells was moderately increased after 24 hrs heparin stimulation. It is suggested that these mechanisms are of major importance for the anticoagulant function of heparins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896252

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  26 in total

1.  Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.

Authors:  Richard C Becker; John H Alexander; Youfu Li; Thomas Robertson; Satoshi Kunitada; Frederick A Spencer; Hongqiu Yang; Robert A Harrington
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

2.  Tissue factor pathway inhibitor in childhood nephrotic syndrome.

Authors:  Mohamed M Al-Mugeiren; Abdel Galil M Abdel Gader; Saud A Al-Rasheed; Abdullah A Al-Salloum
Journal:  Pediatr Nephrol       Date:  2006-03-31       Impact factor: 3.714

3.  Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.

Authors:  Christoph A Ritter; Bernhard Sperker; Markus Grube; Dana Dressel; Christiane Kunert-Keil; Heyo K Kroemer
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

4.  Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.

Authors:  YouFu Li; Miguel Rodriquez; Frederick A Spencer; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2002-10       Impact factor: 2.300

Review 5.  How it all starts: Initiation of the clotting cascade.

Authors:  Stephanie A Smith; Richard J Travers; James H Morrissey
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-05-28       Impact factor: 8.250

6.  Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor.

Authors:  You fu Li; Frederick A Spencer; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

7.  Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

Authors:  Michiel J B Kemme; Jacobus Burggraaf; Rik C Schoemaker; Cornelis Kluft; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

8.  A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor.

Authors:  Offer Erez; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Francesca Gotsch; Juan Pedro Kusanovic; Nandor Gabor Than; Shali Mazaki-Tovi; Edi Vaisbuch; Zoltan Papp; Bo Hyun Yoon; Yu Mi Han; Debra Hoppensteadt; Jawed Fareed; Sonia S Hassan; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2008-10

9.  Tissue factor and its natural inhibitor in pre-eclampsia and SGA.

Authors:  Offer Erez; Roberto Romero; Debra Hoppensteadt; Nandor Gabor Than; Jawed Fareed; Shali Mazaki-Tovi; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Sung-Su Kim; Bo Hyun Yoon; Sonia S Hassan; Francesca Gotsch; Lara Friel; Edi Vaisbuch; Juan Pedro Kusanovic
Journal:  J Matern Fetal Neonatal Med       Date:  2008-12

10.  Rational design of low-molecular weight heparins with improved in vivo activity.

Authors:  Mallik Sundaram; Yiwei Qi; Zachary Shriver; Dongfang Liu; Ganlin Zhao; Ganesh Venkataraman; Robert Langer; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.